1-855-378-42281-855-378-4228
One of the out-patient rehabilitation options for individuals in Croswell struggling with opioid abuse and addiction is called opioid maintenance therapy. Licensed centers and doctors are certified to dispense specific meds to opioid dependent individuals, many of which are opioids also and are addictive. In low amounts however, the client doesn't experience high feelings but also does not have severe cravings and isn't experiencing opioid withdrawal. Methadone is the first med used for this reason, but there are alternative options currently to choose from.
Methadone is an opioid and is meant to be taken at an outpatient clinic licensed to dispense the med, that is taken daily in liquid or pill form. The cost of the drug is about one hundred and fifty dolloars a month. Buprenorphine is also an opiate based med, and is in pill form often taken every other day. But different from Methadone which can only be given in well-regulated clinics, Buprenorphine can be prescribed and administered in doctor's offices. The cost monthly of buprenorphine is around $300.00 /month for the generic version of the medication. There is also a version of buprenorphine that contains the ingredient naloxone, that is a drug that reverses the effects of opioids. An individual taking this version of the drug, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It too is taken daily, and costs approximately $450 per month. Naltrexone is an additional medication taken in opioid maintenance therapy, but unlike the other medications mentioned it is an opiate blocker and is not an opiate. A person has the choice to take this drug as a monthly shot, which is called Vivitrol. As an opioid blocker, the drug prevents someone from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 /month.
For All Alcohol and Drug Treatment Facilities In Croswell, Click Here.
